It can be hypothesized that the effect of the p.736 V variant on hepcidin levels is magnified in NAFLD patients by the induction of hepcidin transcription due to overweight, liver steatosis, and subclinical inflammation [15]. The gene discussed is HAMP; the disease is metabolic dysfunction-associated steatotic liver disease.